卡馬西平: Difference between revisions
From SEHK Wiki
No edit summary |
No edit summary |
||
| Line 115: | Line 115: | ||
*Gynecomastia | *Gynecomastia | ||
*galactorrhea | *galactorrhea | ||
==Pharmacokinetics== | |||
{|class="wikitable" | |||
!Oral bioavailability | |||
|Carbamazepine is slowly but well absorbed after oral administration. It is about 70 to 80% bound to plasma proteins. | |||
|- | |||
!Onset of action | |||
|Its plasma half-life is about 30 hours when it is given as single dose, but it is a strong inducer of hepatic enzymes and the mean plasma half-life on repeated dosage is about 12 to 24 hours. | |||
|- | |||
!Metabolism | |||
|Metabolized in the liver by cytochrome P450 isoenzymes CYP3A4 and CYP2C8. | |||
|- | |||
!Elimination half-life | |||
|Excreted in the urine almost entirely in the form of its metabolites; some are also excreted in faeces. | |||
|} | |||
Revision as of 02:37, 5 October 2020
Carbamazepine is an anticonvulsant medication used primarily in the treatment of epilepsy and neuropathic pain. Carbamazepine appears to work as well as phenytoin and valproate for focal and generalized seizures. It is not effective for absence or myoclonic seizures. It is used in schizophrenia and as a second-line agent in the management of bipolar disorder unresponsive to lithium.
Pronunciation
Carbamazepine 200mg
Carbamazepine controlled-released 200mg (TEGRETOL CR 200mg)
| Generic Name 藥名 | HA Code 藥物代碼 | Classification藥物分類 |
|---|---|---|
| Carbamazepine Suspension 100mg/5ml | CARB49 | P1S1S3 |
Mechanism of Action
Anticonvulsant medication. It is a sodium channel blocker. It binds to sodium channels and suppresses repetitive neuronal firing.
Dosage
1. Epilepsy
| Oral | initially 100 – 200 mg 1-2 times daily, increased slowly by increments of up 200 mg daily every week to an usual maintenance dose of 0.8 – 1.2 g daily in divided doses; up to 2 g daily may occasionally be necessary. |
|---|---|
| By rectum | for short-term use (Max. 7 days) when oral therapy temporarily not possible; 125-mg suppository approximately equivalent to 100-mg tablet, but final adjustment should always depend on clinical response. Max. 1 g daily in 4 divided doses. |
| Elderly | reduce initial dose. |
| Child | the usual daily dose may be given according to age as follows: |
| • Up to 1 year: 100 to 200 mg | |
| • 1 to 5 years: 200 to 400 mg | |
| • 5 to 10 years: 400 to 600 mg | |
| • 10 to 15 years: 0.6 to 1 g | |
| • Over 15 years: usual adult doses | |
| The maximum recommended daily dose, according to age, is as follows: | |
| • Up to 6 years: 35 mg/kg | |
| • 6 to 15 years: 1 g | |
| • Over 15 years: 1.2 g |
2. Trigeminal neuralgia
| Oral | initially 100 mg 1-2 times daily, increased gradually according to response; usual dose 200 mg 3-4 times daily, up to 1.6 g daily in some patients |
|---|
3. Bipolar disorder
| Oral | initially 400 mg daily in divided doses increased until symptoms controlled; usual range 400-600 mg daily; max. 1.6 g daily |
|---|
4. Treatment of alcohol withdrawal
| Oral | initially 400 mg daily in divided doses increased until symptoms controlled; usual range 400-600 mg daily; max. 1.6 g daily |
|---|
5. Diabetic neuropathy
| Oral | initially 100 mg 1-2 times daily, increased gradually according to response; usual dose 200 mg 3-4 times daily, up to 1.6 g daily in some patients |
|---|
| Note | Plasma concentration for optimum response 4-12 mg/litre (20-50 micromol/litre) |
|---|
Side Effects
Common side effects include:
- Drowsiness, dizziness and headaches
- Gastrointestinal disturbances, such as nausea and vomiting
- The loss of full control of bodily movements (motor coordination impairment)
- Increased risks of hyponatremia and SIADH
- Blood disorders (such as decreased white blood cell or platelet counts)
Serious side effects may include:
- Skin rashes, exfoliative dermatitis, epidermal necrolysis, Stevens-Johnson syndrome, and SLE
- Decreased bone marrow function
- Suicidal thoughts
- Abnormal heart rhythms
- Blurry or double vision, nystagmus
- Male infertility
- Osteoporosis
- Gynecomastia
- galactorrhea
Pharmacokinetics
| Oral bioavailability | Carbamazepine is slowly but well absorbed after oral administration. It is about 70 to 80% bound to plasma proteins. |
|---|---|
| Onset of action | Its plasma half-life is about 30 hours when it is given as single dose, but it is a strong inducer of hepatic enzymes and the mean plasma half-life on repeated dosage is about 12 to 24 hours. |
| Metabolism | Metabolized in the liver by cytochrome P450 isoenzymes CYP3A4 and CYP2C8. |
| Elimination half-life | Excreted in the urine almost entirely in the form of its metabolites; some are also excreted in faeces. |
